Treatment Set TS330583 is a Intradermal; Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Antigen Laboratories, Inc.. The primary component is Carya Alba Pollen; Carya Illinoinensis Pollen; Poa Pratensis Pollen; Cynodon Dactylon Pollen; Sorghum Halepense Pollen; Dermatophagoides Pteronyssinus; Dermatophagoides Farinae; Rumex Acetosella Pollen.
| Product ID | 49288-0699_89f9e682-acd9-4cc7-982d-c32f69b33b07 | 
| NDC | 49288-0699 | 
| Product Type | Human Prescription Drug | 
| Proprietary Name | Treatment Set TS330583 | 
| Generic Name | Treatment Set Ts330583 | 
| Dosage Form | Injection, Solution | 
| Route of Administration | INTRADERMAL; SUBCUTANEOUS | 
| Marketing Start Date | 1986-10-31 | 
| Marketing Category | BLA / BLA | 
| Application Number | BLA102223 | 
| Labeler Name | Antigen Laboratories, Inc. | 
| Substance Name | CARYA ALBA POLLEN; CARYA ILLINOINENSIS POLLEN; POA PRATENSIS POLLEN; CYNODON DACTYLON POLLEN; SORGHUM HALEPENSE POLLEN; DERMATOPHAGOIDES PTERONYSSINUS; DERMATOPHAGOIDES FARINAE; RUMEX ACETOSELLA POLLEN | 
| Active Ingredient Strength | 0 g/mL; g/mL; [BAU]/mL; [BAU]/mL; g/mL; [AU]/mL; [AU]/mL; g/mL | 
| Pharm Classes | Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Standardized Pollen Allergenic Extract [EPC],Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Standardized Insect Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Antigens, Dermatophagoides [CS],Insect Proteins [CS],Allergens [CS],Allergens [CS],Insect Proteins [CS],Standardized Insect Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Antigens, Dermatophagoides [CS],Non-Standardized Pollen Allergenic Extract [EPC],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Increased Histamine Release [PE],Allergens [CS] | 
| NDC Exclude Flag | E | 
| Listing Certified Through | 2017-12-31 | 
| Marketing Start Date | 1986-10-31 | 
| NDC Exclude Flag | N | 
| Sample Package? | N | 
| Marketing Category | BLA | 
| Application Number | BLA102223 | 
| Product Type | HUMAN PRESCRIPTION DRUG | 
| Marketing Start Date | 1986-10-31 | 
| Inactivation Date | 2019-10-21 | 
| Ingredient | Strength | 
|---|---|
| CARYA ALBA POLLEN | .001 g/mL |